SGLT2 inhibitor empagliflozin can be used to treat insulin resistance in the brain, finds study

Overweight or obesity, unwanted distribution of body fat and the development of type 2 diabetes are often associated with a decreased effect of the hormone insulin in many organs, including the brain (insulin resistance). So far there is no treatment to restore insulin sensitivity in the brain, which plays a key role in controlling metabolism. … Read more

New drug targeting LF and onchocerciasis begins its first in human trial in Liverpool

A new drug developed by a partnership led by LSTM, which targets neglected tropical diseases, lymphatic filariasis and onchocerciasis, has begun its first human trial. Lymphatic filariasis and onchocerciasis are debilitating diseases that affect more than 150 million people worldwide. Both are caused by parasitic worms, and this specific drug AWZ1066S was designed to targetWolbachia, … Read more